Casdin Partners Master Fund, L Acquires 250,000 Shares of Standard BioTools (NASDAQ:LAB) Stock

Posted by Alphonse Anthony on Nov 18th, 2025

Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) Director Casdin Partners Master Fund, L acquired 250,000 shares of the company’s stock in a transaction on Friday, November 14th. The shares were acquired at an average price of $1.24 per share, for a total transaction of $310,000.00. Following the completion of the acquisition, the director directly owned 62,750,000 shares in the company, valued at $77,810,000. The trade was a 0.40% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Casdin Partners Master Fund, L also recently made the following trade(s):

On Monday, November 17th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.22 per share, with a total value of $274,500.00.
On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.20 per share, with a total value of $540,000.00.
On Wednesday, November 12th, Casdin Partners Master Fund, L acquired 375,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.19 per share, for a total transaction of $446,250.00.
On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.20 per share, with a total value of $360,000.00.
On Monday, November 10th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.17 per share, with a total value of $321,750.00.
On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.12 per share, for a total transaction of $252,000.00.
On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.29 per share, for a total transaction of $129,000.00.
On Wednesday, September 3rd, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.27 per share, with a total value of $317,500.00.
On Tuesday, August 26th, Casdin Partners Master Fund, L acquired 125,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.26 per share, for a total transaction of $157,500.00.
On Monday, August 25th, Casdin Partners Master Fund, L bought 200,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.24 per share, for a total transaction of $248,000.00.

Standard BioTools Stock Down 2.4%

Shares of LAB traded down $0.03 during mid-day trading on Monday, hitting $1.21. The stock had a trading volume of 1,308,580 shares, compared to its average volume of 1,658,374. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.25. The company has a market cap of $465.32 million, a PE ratio of -3.78 and a beta of 1.25. The company’s fifty day simple moving average is $1.29 and its two-hundred day simple moving average is $1.23.

Institutional Trading of Standard BioTools

A number of large investors have recently modified their holdings of the company. Jump Financial LLC bought a new stake in Standard BioTools in the 1st quarter valued at about $26,000. Russell Investments Group Ltd. increased its stake in shares of Standard BioTools by 2,989.0% in the third quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after purchasing an additional 24,211 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Standard BioTools by 115.6% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after buying an additional 14,541 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Standard BioTools by 103.6% during the third quarter. Federated Hermes Inc. now owns 28,545 shares of the company’s stock worth $37,000 after buying an additional 14,523 shares during the period. Finally, CWM LLC boosted its position in shares of Standard BioTools by 101.8% during the first quarter. CWM LLC now owns 29,705 shares of the company’s stock worth $32,000 after buying an additional 14,984 shares during the period. Institutional investors and hedge funds own 53.74% of the company’s stock.

Wall Street Analysts Forecast Growth

LAB has been the subject of a number of research reports. Cowen downgraded shares of Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Standard BioTools in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Finally, TD Cowen cut their target price on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a report on Wednesday, November 5th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $1.35.

Check Out Our Latest Stock Report on LAB

Standard BioTools Company Profile

(Get Free Report)

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.